Life Sciences

  • June 05, 2026

    IRhythm Inks $45M Deal With Investors In Heart Device Suit

    IRhythm Technologies Inc. investors asked a California federal judge to preliminarily greenlight a $45 million settlement resolving allegations the digital healthcare company inflated stock prices with misrepresentations about its heart-event monitoring device, noting the deal is a favorable result that warrants approval, given the possibility of no recovery. 

  • June 05, 2026

    Fed. Circ. Backs Melinta Patent Win In Injections Case

    Nexus Pharmaceuticals lost its appeal of an Illinois federal judge's finding that it infringed a pair of patents relating to a line of injections that treat infections, after the Federal Circuit on Friday shot down the drugmaker's challenge to the lower court's interpretation of key patent terms.

  • June 05, 2026

    Sanofi Eczema Drug Suits Consolidated, Sent To NJ Fed Court

    The Judicial Panel on Multidistrict Litigation has sent to federal court in New Jersey suits against Regeneron Pharmaceuticals and Sanofi-Aventis alleging the eczema drug Dupixent causes a rare type of non-Hodgkin lymphoma.

  • June 05, 2026

    CMS Hemp Program Foes Take Standing Fight To DC Circ.

    A group challenging a Centers for Medicare & Medicaid Services program to give patients access to federally legal hemp products will bring their case to the D.C. Circuit Court of Appeals after a federal judge tossed their petition for lack of standing last month.

  • June 05, 2026

    Health Funds Ink $5.5M Generic Drug Deal With Breckenridge

    A proposed class of end-payers who allegedly overpaid for generic drugs have asked a federal court for preliminary approval of a $5.5 million settlement with Breckenridge Pharmaceutical Inc., though notifying class members and seeking final approval would wait until the process could be combined with another settlement, the plaintiffs said Thursday.

  • June 05, 2026

    Don't Miss It: Hogan Lovells, Cooley Steer Hot Deals

    A lot can happen in the world of mergers and acquisitions and equity fundraising over the course of a couple of weeks, and it's difficult to keep up with all the deals.

  • June 05, 2026

    UK Litigation Roundup: Here's What You Missed In London

    The past week in London has seen the U.K.'s oldest Indian restaurant launch an appeal against King Charles III's property company in an effort to stop its eviction, trustees of a bankrupt former EY tax partner file a claim against his wife, and 37 leading insurers bring a lawsuit against agrichemical company Syngenta over an insurance dispute. Here, Law360 looks at these and other new claims in the U.K.

  • June 04, 2026

    No 'Conspiracy To Hide Asbestos' In Talc, J&J Atty Tells Jury

    An attorney for Johnson & Johnson said Thursday during closing arguments of a six-week bellwether trial that the only way three women's deadly ovarian cancers were caused by the company's talc would be a vast worldwide conspiracy to hide that asbestos is present in the products, but it just "doesn't make sense."

  • June 04, 2026

    Generics Cos. Get More Freedom In High Court Patent Ruling

    The U.S. Supreme Court's decision Thursday shutting down a patent case involving a generic heart drug that uses a so-called skinny label establishes a road map for generics companies to avoid such suits and creates hurdles for branded companies pursuing infringement litigation, attorneys say.

  • June 04, 2026

    Amgen Won't Face 'Nonsensical' Rodent Antibody IP At Trial

    A Delaware federal judge has trimmed Harbour Medical's infringement suit against an Amgen unit just days before trial, saying two of the company's mouse antibody patents are indefinite based on a term that "everyone agrees" is "nonsensical."

  • June 04, 2026

    Eli Lilly's 'Overbroad' Weight Drug TM Deal Rejected

    A Washington federal judge has refused to sign off on a deal to settle trademark claims brought by Eli Lilly against two Seattle-area medical clinics, saying the associated consent decree was "overbroad" and contained an even more sweeping injunction.

  • June 04, 2026

    Doctor Lied About Risky 'Basket Weave' Surgery, Patients Say

    Six patients accused a Seattle doctor of overstating his "basket weave" surgery technique meant to treat a painful condition known as "slipping rib syndrome," claiming in a Washington state lawsuit that Dr. Madhankumar Kuppusamy failed to disclose the experimental nature of the procedure that left some patients with serious injuries.

  • June 04, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    New York lawmakers gave final approval to legislation designed to curb the flow of illicit product into the state's cannabis market; Iowa's governor signed into law a bill to double the number of licensed medical cannabis dispensaries; and Louisiana legislation allowing terminally ill patients to access medical marijuana became law. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • June 04, 2026

    Fed. Circ. Invalidates Spinal Implant Patent Claims

    The Federal Circuit on Thursday invalidated patent claims covering parts used to make expandable implant devices in spinal fusion surgeries that were the basis of a $9.5 million jury verdict against Life Spine Inc. and that had been upheld by the Patent Trial and Appeal Board.

  • June 04, 2026

    Judge Questions Fees In Abbott Investors' $40M Formula Deal

    An Illinois federal judge on Thursday granted final approval to most of Abbott Laboratories' $40 million deal to resolve shareholder claims over its management of a 2022 infant formula crisis, but questioned whether the settlement's corporate reforms justify a $15 million fee award for the investors' attorneys.

  • June 04, 2026

    Inotiv Gets Cash Access To Pursue Ch. 11 Prepack Track

    Bankrupt drug research and development company Inotiv Inc. received interim approval on Thursday to access a $25 million bankruptcy loan as it pursues a prepackaged balance sheet restructuring in Texas court.

  • June 04, 2026

    Catalent Investors Say No Objections To $78M Deal, Fee Bid

    Investors seeking final approval of a $78 million securities fraud settlement with Catalent told a New Jersey federal court that the proposed deal and fee bid are free of objections, arguing the positive response further supports the court's approval of the settlement.

  • June 04, 2026

    US Middle Market PE Surge Expected After Strong 2025

    U.S. middle market private equity dealmakers are signaling renewed optimism, with the vast majority expecting a meaningful jump in buyout activity over the next two years after a robust 2025, according to survey results published on Thursday. 

  • June 04, 2026

    Supreme Court Shuts Down 'Skinny Label' Drug Patent Suit

    The U.S. Supreme Court on Thursday ended a patent suit over Hikma Pharmaceuticals USA Inc.'s generic version of a heart drug that uses a so-called skinny label, saying Amarin Pharma Inc. had not plausibly alleged that Hikma encouraged healthcare providers to infringe its patents.

  • June 03, 2026

    AbbVie Loses Miss. Discount Drug Law Challenge For Good

    A Mississippi federal judge on Wednesday threw out a suit brought by AbbVie and other pharmaceutical manufacturers that participate in Medicaid challenging a law barring their interference with the distribution of discounted prescriptions to pharmacies serving low-income patients.

  • June 03, 2026

    Medtronic Unit Must Face Bellwether Hernia Mesh Claims

    A Massachusetts federal judge has largely cleared the way for bellwether claims in multidistrict litigation over Covidien's hernia mesh, finding that a reasonable jury could find the Medtronic subsidiary failed to adequately warn physicians about certain risks.

  • June 03, 2026

    Balwani Takes Theranos Conviction Challenge To Justices

    Former Theranos executive Ramesh "Sunny" Balwani is asking the U.S. Supreme Court to review his criminal fraud conviction and nearly 13-year prison sentence, arguing that the Ninth Circuit used the wrong review doctrine in rejecting his argument that prosecutors had failed to correct allegedly false testimony given by investor victims.

  • June 03, 2026

    'This Is Their Document': Jury Told J&J Docs Prove Talc Lies

    Counsel for the families of three women who died of ovarian cancer delivered closing arguments Wednesday in their six-week-long bellwether lawsuit against Johnson & Johnson, telling jurors that decades-old internal documents prove the company hid that its talc was contaminated with asbestos.

  • June 03, 2026

    Squires Institutes 3 Patent Reviews, Denies 3 Others

    U.S. Patent and Trademark Office Director John Squires on Tuesday granted three requests for review of patents under the America Invents Act, while turning down three other petitions.

  • June 03, 2026

    Ill. Court Blocks Fla. Suit Targeting Gender Care Policies

    An Illinois federal judge blocked the Florida attorney general's lawsuit targeting medical groups' policies on youth gender-affirming care, saying there's sufficient jurisdiction over Sunshine State officials because of a potential nationwide chilling effect the enforcement action caused.

Expert Analysis

  • Series

    Officiating Football Makes Me A Better Lawyer

    Author Photo

    Though they may seem to have little in common, officiating football has sharpened many of the same skills that define effective lawyering in management-side labor and employment: preparation, judgment, composure, credibility and ability to make difficult decisions in real time, says Josh Nadreau at Fisher Phillips.

  • Fresenius Ruling May Shift Anti-Kickback Enforcement

    Author Photo

    The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.

  • Written Consent Ruling May Signal Change For Telemarketing

    Author Photo

    The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.

  • Series

    Law School's Missed Lessons: How To Draft Pleadings

    Author Photo

    Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.

  • At The Fed. Circ., Means-Plus-Function Is Not Quite Dead

    Author Photo

    Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.

  • E-Discovery Quarterly: Recent Rulings On ESI Control

    Author Photo

    Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

  • 2 Discovery Rulings Break With Heppner On AI Privilege Issue

    Author Photo

    While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.

  • Series

    Isshin-Ryu Karate Makes Me A Better Lawyer

    Author Photo

    My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.

  • Microplastics On Water Contaminant List Could Spur Claims

    Author Photo

    The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.

  • USPTO's AI Search Pilot May Reshape Patent Filing Strategy

    Author Photo

    The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.

  • Peptide Policy Is Shifting Toward Sanctioned Compounding

    Author Photo

    The policy landscape for peptides is undergoing a significant shift under the Trump administration, moving toward a complex system of verified compounding and complementary enforcement that will likely bring peptides firmly back into the sphere of legitimate consumer products, say attorneys at Sheppard.

  • Keys To Building Defensible Psychedelic Therapy Programs

    Author Photo

    Given the rapidly evolving legal environment for psychedelic therapies and heightened liability and compliance risks facing providers, meticulous documentation, robust risk management protocols, and proactive engagement with professional organizations and insurers are essential strategies, say Kimberly Chew at Husch Blackwell and L. Alison McInnes at Mindful Health Solutions.

  • Opinion

    State Bars Need To Get Specific About AI Confidentiality

    Author Photo

    Lawyers need to put actual client information into artificial intelligence tools to get their full value, but they cannot confidently do so until state bars offer clear, formal authority on which plan tiers of the three most popular generative AI tools are safe to use when sharing specific client details, says attorney Nick Berk.

  • Series

    Alpine Skiing Makes Me A Better Lawyer

    Author Photo

    Skiing has shaped habits I rely on daily as an attorney — focus, resilience and the ability to remain steady when circumstances shift rapidly — and influences the way I approach legal strategy, client counseling and teamwork, says Isaku Begert at Marshall Gerstein.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.